Stifel Nicolaus Has Lowered Expectations for Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus ...
Bolt Biotherapeutics price target lowered to $1.25 from $1.50 at Stifel
Stifel lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of ...
Bolt Biotherapeutics (NASDAQ:BOLT) Given “Neutral” Rating at HC Wainwright
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at HC ...
Yahoo Finance8d
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $15.9 million in its fourth quarter. The Redwood City, California-based ...
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest ...
Hosted on MSN1mon
Bolt Projects Holdings faces Nasdaq delisting risk
Bolt Projects Holdings, Inc., an industrial organic chemicals firm, has been notified by The Nasdaq Stock Market LLC of a potential delisting due to non-compliance with market value requirements.
Morningstar12d
Bolt Metals Corp PCRCF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...